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Supplementary Figure 1 Legend  
Anti-CS titres with interpolated fit of log-transformed values (3=1000 EU/mL, 2=100 EU/mL, 1=10 EU/mL, 0=1 
EU/mL). Time=0 is 1 month after the final vaccination. 
Supplementary Figure 2 Legend  
For each model, anti-CS titres were divided into two groups, above and below a dichotomization point (x axis) and 
goodness of fit for each model measured (log likelihood, y axis). 
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Supplementary figure 1: Individual anti-CS titres from the first 20 RTS,S/AS01E vaccinees  
 
Time (months)
An
ti-
C
S 
Ti
tre
 (l
og
 tr
an
sf
or
m
ed
 E
U
/m
L)
0 6 12 18 0 6 12 18 0 6 12 18 0 6 12 18 0 6 12 18
0.1
1
10
100
1,000
0.1
1
10
100
1,000
0.1
1
10
100
1,000
0.1
1
10
100
1,000
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
Supplementary figure 2: Goodness fit log likelihood and dichotomization point for anti-CS 
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